Structural remodeling in the development of chronic systolic heart failure: Implication for treatment

Inder S. Anand, Viorel G. Florea

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Ventricular remodeling is a complex process that results from interactions between the initial myocardial injury and neurohormonal factors that are capable of modifying the cardiomyocyte phenotype and of inducing changes in the extracellular matrix. At the cellular level, myocyte hypertrophy, necrosis, apoptosis, interstitial fibrosis, and degradation of collagen are the major features of myocardial remodeling. Each of these components of the remodeling process contributes importantly to the development and progression of heart failure (HF). At the level of the ventricular chamber, remodeling is associated with progressive ventricular hypertrophy, enlargement, and cavity distortion that is directly related to deterioration in ventricular performance and to long-term adverse clinical outcomes. The mechanisms responsible for ventricular remodeling and deterioration of ventricular structure and function are not entirely clear, but are related to neurohormonal and cytokine activation. These factors in combination with increased wall stress and mechanical stretch of the myocytes upregulate a large number of signaling pathways. This leads to structural and functional changes in the myocyte and nonmyocyte compartments, contributing to ventricular dysfunction and the progression of HF. Although, initially, it may be compensatory in certain pressure and volume-overload conditions, progressive ventricular remodeling is ultimately a maladaptive process. After myocardial infarction, however, progressive hypertrophy and remodeling of noninfarcted myocardium may be harmful from the start. Ventricular remodeling has emerged as an important therapeutic target and a credible surrogate end point in HF. Agents that have beneficial effects in HF also generally attenuate or reverse ventricular remodeling, whereas agents that fail to improve clinical outcomes either have no effect on remodeling or have been associated with adverse remodeling. An important goal in the treatment of HF is to slow or reverse remodeling to improve long-term outcome.

Original languageEnglish (US)
Title of host publicationCongestive Heart Failure and Cardiac Transplantation
Subtitle of host publicationClinical, Pathology, Imaging and Molecular Profiles
PublisherSpringer International Publishing
Pages247-265
Number of pages19
ISBN (Electronic)9783319445779
ISBN (Print)9783319445755
DOIs
StatePublished - Jun 1 2017

Fingerprint

Systolic Heart Failure
Ventricular Remodeling
Heart Failure
Muscle Cells
Hypertrophy
Ventricular Dysfunction
Mechanical Stress
Ventricular Function
Treatment Failure
Cardiac Myocytes
Extracellular Matrix
Myocardium
Fibrosis
Necrosis
Up-Regulation
Collagen
Biomarkers
Myocardial Infarction
Apoptosis
Cytokines

Keywords

  • Extracellular matrix
  • Heart failure
  • Mechanisms
  • Myocyte hypertrophy
  • Reverse remodeling
  • Ventricular remodeling

Cite this

Anand, I. S., & Florea, V. G. (2017). Structural remodeling in the development of chronic systolic heart failure: Implication for treatment. In Congestive Heart Failure and Cardiac Transplantation: Clinical, Pathology, Imaging and Molecular Profiles (pp. 247-265). Springer International Publishing. https://doi.org/10.1007/978-3-319-44577-9_17

Structural remodeling in the development of chronic systolic heart failure : Implication for treatment. / Anand, Inder S.; Florea, Viorel G.

Congestive Heart Failure and Cardiac Transplantation: Clinical, Pathology, Imaging and Molecular Profiles. Springer International Publishing, 2017. p. 247-265.

Research output: Chapter in Book/Report/Conference proceedingChapter

Anand, IS & Florea, VG 2017, Structural remodeling in the development of chronic systolic heart failure: Implication for treatment. in Congestive Heart Failure and Cardiac Transplantation: Clinical, Pathology, Imaging and Molecular Profiles. Springer International Publishing, pp. 247-265. https://doi.org/10.1007/978-3-319-44577-9_17
Anand IS, Florea VG. Structural remodeling in the development of chronic systolic heart failure: Implication for treatment. In Congestive Heart Failure and Cardiac Transplantation: Clinical, Pathology, Imaging and Molecular Profiles. Springer International Publishing. 2017. p. 247-265 https://doi.org/10.1007/978-3-319-44577-9_17
Anand, Inder S. ; Florea, Viorel G. / Structural remodeling in the development of chronic systolic heart failure : Implication for treatment. Congestive Heart Failure and Cardiac Transplantation: Clinical, Pathology, Imaging and Molecular Profiles. Springer International Publishing, 2017. pp. 247-265
@inbook{3141f7ae28b945b18e3c0bd73980aaa9,
title = "Structural remodeling in the development of chronic systolic heart failure: Implication for treatment",
abstract = "Ventricular remodeling is a complex process that results from interactions between the initial myocardial injury and neurohormonal factors that are capable of modifying the cardiomyocyte phenotype and of inducing changes in the extracellular matrix. At the cellular level, myocyte hypertrophy, necrosis, apoptosis, interstitial fibrosis, and degradation of collagen are the major features of myocardial remodeling. Each of these components of the remodeling process contributes importantly to the development and progression of heart failure (HF). At the level of the ventricular chamber, remodeling is associated with progressive ventricular hypertrophy, enlargement, and cavity distortion that is directly related to deterioration in ventricular performance and to long-term adverse clinical outcomes. The mechanisms responsible for ventricular remodeling and deterioration of ventricular structure and function are not entirely clear, but are related to neurohormonal and cytokine activation. These factors in combination with increased wall stress and mechanical stretch of the myocytes upregulate a large number of signaling pathways. This leads to structural and functional changes in the myocyte and nonmyocyte compartments, contributing to ventricular dysfunction and the progression of HF. Although, initially, it may be compensatory in certain pressure and volume-overload conditions, progressive ventricular remodeling is ultimately a maladaptive process. After myocardial infarction, however, progressive hypertrophy and remodeling of noninfarcted myocardium may be harmful from the start. Ventricular remodeling has emerged as an important therapeutic target and a credible surrogate end point in HF. Agents that have beneficial effects in HF also generally attenuate or reverse ventricular remodeling, whereas agents that fail to improve clinical outcomes either have no effect on remodeling or have been associated with adverse remodeling. An important goal in the treatment of HF is to slow or reverse remodeling to improve long-term outcome.",
keywords = "Extracellular matrix, Heart failure, Mechanisms, Myocyte hypertrophy, Reverse remodeling, Ventricular remodeling",
author = "Anand, {Inder S.} and Florea, {Viorel G.}",
year = "2017",
month = "6",
day = "1",
doi = "10.1007/978-3-319-44577-9_17",
language = "English (US)",
isbn = "9783319445755",
pages = "247--265",
booktitle = "Congestive Heart Failure and Cardiac Transplantation",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Structural remodeling in the development of chronic systolic heart failure

T2 - Implication for treatment

AU - Anand, Inder S.

AU - Florea, Viorel G.

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Ventricular remodeling is a complex process that results from interactions between the initial myocardial injury and neurohormonal factors that are capable of modifying the cardiomyocyte phenotype and of inducing changes in the extracellular matrix. At the cellular level, myocyte hypertrophy, necrosis, apoptosis, interstitial fibrosis, and degradation of collagen are the major features of myocardial remodeling. Each of these components of the remodeling process contributes importantly to the development and progression of heart failure (HF). At the level of the ventricular chamber, remodeling is associated with progressive ventricular hypertrophy, enlargement, and cavity distortion that is directly related to deterioration in ventricular performance and to long-term adverse clinical outcomes. The mechanisms responsible for ventricular remodeling and deterioration of ventricular structure and function are not entirely clear, but are related to neurohormonal and cytokine activation. These factors in combination with increased wall stress and mechanical stretch of the myocytes upregulate a large number of signaling pathways. This leads to structural and functional changes in the myocyte and nonmyocyte compartments, contributing to ventricular dysfunction and the progression of HF. Although, initially, it may be compensatory in certain pressure and volume-overload conditions, progressive ventricular remodeling is ultimately a maladaptive process. After myocardial infarction, however, progressive hypertrophy and remodeling of noninfarcted myocardium may be harmful from the start. Ventricular remodeling has emerged as an important therapeutic target and a credible surrogate end point in HF. Agents that have beneficial effects in HF also generally attenuate or reverse ventricular remodeling, whereas agents that fail to improve clinical outcomes either have no effect on remodeling or have been associated with adverse remodeling. An important goal in the treatment of HF is to slow or reverse remodeling to improve long-term outcome.

AB - Ventricular remodeling is a complex process that results from interactions between the initial myocardial injury and neurohormonal factors that are capable of modifying the cardiomyocyte phenotype and of inducing changes in the extracellular matrix. At the cellular level, myocyte hypertrophy, necrosis, apoptosis, interstitial fibrosis, and degradation of collagen are the major features of myocardial remodeling. Each of these components of the remodeling process contributes importantly to the development and progression of heart failure (HF). At the level of the ventricular chamber, remodeling is associated with progressive ventricular hypertrophy, enlargement, and cavity distortion that is directly related to deterioration in ventricular performance and to long-term adverse clinical outcomes. The mechanisms responsible for ventricular remodeling and deterioration of ventricular structure and function are not entirely clear, but are related to neurohormonal and cytokine activation. These factors in combination with increased wall stress and mechanical stretch of the myocytes upregulate a large number of signaling pathways. This leads to structural and functional changes in the myocyte and nonmyocyte compartments, contributing to ventricular dysfunction and the progression of HF. Although, initially, it may be compensatory in certain pressure and volume-overload conditions, progressive ventricular remodeling is ultimately a maladaptive process. After myocardial infarction, however, progressive hypertrophy and remodeling of noninfarcted myocardium may be harmful from the start. Ventricular remodeling has emerged as an important therapeutic target and a credible surrogate end point in HF. Agents that have beneficial effects in HF also generally attenuate or reverse ventricular remodeling, whereas agents that fail to improve clinical outcomes either have no effect on remodeling or have been associated with adverse remodeling. An important goal in the treatment of HF is to slow or reverse remodeling to improve long-term outcome.

KW - Extracellular matrix

KW - Heart failure

KW - Mechanisms

KW - Myocyte hypertrophy

KW - Reverse remodeling

KW - Ventricular remodeling

UR - http://www.scopus.com/inward/record.url?scp=85054702833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054702833&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-44577-9_17

DO - 10.1007/978-3-319-44577-9_17

M3 - Chapter

AN - SCOPUS:85054702833

SN - 9783319445755

SP - 247

EP - 265

BT - Congestive Heart Failure and Cardiac Transplantation

PB - Springer International Publishing

ER -